Impact of suture mediated femoral access site closure with the Prostar XL compared to the ProGlide system on outcome in transfemoral aortic valve implantation

Seeger, Julia; Gonska, Birgid; Rodewald, Christoph; Rottbauer, Wolfgang; Wöhrle, Jochen

doi:10.1016/j.ijcard.2016.08.193

Cited by 35 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher rates of AKI associated with PS have been reported in a number of prior studies comparing PS and PG . However, the most recent systematic review of PS and PG was not consistent with this finding .…”

Section: Discussionmentioning

confidence: 58%

“…Seeger et al in their non‐randomized prospective study examined the clinical outcomes of 585 patients treated with either PG or PS following transfemoral TAVR, showing higher rates of major (12.2% vs. 2.3%, p < .01) and minor (17.3% vs. 5.7%, p < .01) vascular complications with the use of PS compared to PG, in addition to lower rates of bleeding events and acute kidney injury. Of note, they also showed a lower in‐hospital mortality (2% vs. 5.9%, p = .01) in the PG group . In contrast, Barbanti et al previously shown higher rates of vascular complications with the PG device compared to PS (24.0% vs. 11.8%) …”

Section: Discussionmentioning

confidence: 85%

“…Higher rates of AKI associated with PS have been reported in a number of prior studies comparing PS and PG. 10,19,25 However, the most recent systematic review of PS and PG was not consistent with this finding. 13 Our study indicated a strong association between PS and AKI in both unadjusted and adjusted outcomes within a large randomized cohort.…”

Section: Closure Device: Acute Kidney Injurymentioning

confidence: 81%

“…Of note, they also showed a lower in-hospital mortality (2% vs. 5.9%, p = .01) in the PG group. 19 In contrast, Barbanti et al previously shown higher rates of vascular complications with the PG device compared to PS (24.0% vs. 11.8%). 11 .…”

Section: Closure Device: Vascular Complicationsmentioning

confidence: 99%

See 3 more Smart Citations

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial

Power

Schäfer²,

Guedeney

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

Background/Objective Prostar XL (PS) and ProGlide (PG) are common vascular closure devices (VCD) used in TAVR via transfemoral vascular approach. The impact of these VCD on vascular and bleeding complications remains unclear. Methods The BRAVO‐3 trial randomized 802 patients undergoing transfemoral TAVR. We stratified patients according to type of VCD used and examined the 30‐day incidence of major or minor vascular complications, major bleeding (BARC ≥3b), AKI and major adverse cardiac and cerebrovascular events (MACCE; death, myocardial infarction or stroke). Results A total of 746 (93%) patients were treated with either PS (n = 352, 47%) or PG (n = 394, 53%) VCD, without significant differences in successful deployment rate (PS 322 [91.2%] vs. PG 373 [94.2%] respectively, p = .20). PG was associated with a significantly lower incidence of major or minor vascular complications, compared to PS (adjusted OR: 0.54; 95% CI: 0.37–0.80; p < .01). Rates of acute kidney injury were also lower with the PG device. There was no significant difference between bleeding, MACCE, and death. Conclusions Compared to PS, the PG VCD was associated with a lower rate of major or minor vascular complications and lower rates of AKI after transfemoral TAVR.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 85%

Section: Closure Device: Acute Kidney Injurymentioning

confidence: 81%

Section: Closure Device: Vascular Complicationsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial

Power

Schäfer²,

Guedeney

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…The most recently published trials have demonstrated the superiority of the Proglide device, with Prostar XL having a higher rate of major vascular complications (7.4% vs 1.9%; p<0.001),34 an increased rate of closure device failure (19% vs 4.6%; p<0.01) and higher in-hospital mortality (5.9% vs 2.0%; p=0.01) 35…”

Section: Access Site-related Complicationsmentioning

confidence: 99%

Transcatheter aortic valve implantation: new hope in the management of valvular heart disease

Metaxa

Missouris

2017

Postgraduate Medical Journal

View full text Add to dashboard Cite

Severe calcific aortic stenosis is relatively common, and unless treated with valve replacement it carries an adverse prognosis. A large number of patients, however, are denied surgery due to their advanced age or coexistent medical conditions that increase perioperative cardiovascular risks. Transcatheter aortic valve implantation (TAVI), a technique in which a bioprosthetic valve is inserted via a catheter and implanted within the diseased native aortic valve, is a new therapeutic modality for treatment of older patients with severe symptomatic aortic stenosis and other comorbidities, who have an inherently high surgical risk. This review will provide an overview of the pivotal trials in the development of TAVI; while also investigating important complications and limitations of the procedure and evaluating how new valves are being designed and clinically evaluated, with the ultimate goal of reducing potential complications and expanding the use of TAVI to lower-risk patient cohorts.

show abstract

The Essentials of Femoral Vascular Access and Closure

Meucci¹,

Stolcova²,

Caniato³

et al. 2022

Interventional Cardiology

View full text Add to dashboard Cite

Impact of suture mediated femoral access site closure with the Prostar XL compared to the ProGlide system on outcome in transfemoral aortic valve implantation

Cited by 35 publications

References 16 publications

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial

Transcatheter aortic valve implantation: new hope in the management of valvular heart disease

The Essentials of Femoral Vascular Access and Closure

Contact Info

Product

Resources

About